Survival in Unresectable Hepatocellular Carcinoma Treated With a New Immune Checkpoint and Antiangiogenic Drug Combination

被引：0
|
作者：
Mezzacappa, Catherine [1 ]
机构：
[1] Yale Sch Med, Dept Internal Med, Sect Digest Dis, New Haven, CT 06510 USA
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：350 / 350
页数：1
相关论文
共 50 条
  • [1] Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
    Lee, Pei-Chang
    Chao, Yee
    Chen, Ming-Huang
    Lan, Keng-Hsin
    Lee, Chieh-Ju
    Lee, I-Cheng
    Chen, San-Chi
    Hou, Ming-Chih
    Huang, Yi-Hsiang
    CANCERS, 2020, 12 (01)
  • [2] Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
    Abd El Aziz, Mohamed A.
    Facciorusso, Antonio
    Nayfeh, Tarek
    Saadi, Samer
    Elnaggar, Mohamed
    Cotsoglou, Christian
    Sacco, Rodolfo
    VACCINES, 2020, 8 (04) : 1 - 19
  • [3] Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma
    Ning, Cong
    Zhang, Xinmu
    Wang, Yanyu
    Yang, Xu
    Yang, Xiaobo
    Chao, Jiashuo
    Xun, Ziyu
    Xue, Jingnan
    Wang, Yunchao
    Sun, Huishan
    Li, Yiran
    Zhang, Nan
    Zhu, Chengpei
    Hou, Xiaorong
    Sang, Xinting
    Zhao, Haitao
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : 1461 - 1471
  • [4] Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
    Liu, Ze-Long
    Liu, Jing-Hua
    Staiculescu, Daniel
    Chen, Jiang
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [5] Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review
    Tang, Haowen
    Cao, Yinbiao
    Jian, Yiping
    Li, Xuerui
    Li, Junfeng
    Zhang, Wenwen
    Wan, Tao
    Liu, Zhe
    Tang, Wei
    Lu, Shichun
    BIOSCIENCE TRENDS, 2022, 16 (02) : 130 - 141
  • [6] Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors
    Y. Linda Wu
    Sarah Cappuyns
    Amanda Loh
    Sean Sun
    Sara Lewis
    Max W. Sung
    Myron Schwartz
    Josep M. Llovet
    Deirdre J. Cohen
    BJC Reports, 2 (1):
  • [7] Systemic Chemotherapy with Combination of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor in Unresectable Hepatocellular Carcinoma
    Chon, Hye Yeon
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2024, 83 (02): : 78 - 80
  • [8] Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
    Lee, Pei-Chang
    Chao, Yee
    Chen, Ming-Huang
    Lan, Keng-Hsin
    Lee, I-Cheng
    Hou, Ming-Chih
    Huang, Yi-Hsiang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [9] Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors
    Zhu, Hong-Fei
    Feng, Jin-Kai
    Xiang, Yan-Jun
    Wang, Kang
    Zhou, Li-Ping
    Liu, Zong-Han
    Cheng, Yu-Qiang
    Shi, Jie
    Guo, Wei-Xing
    Cheng, Shu-Qun
    BMC CANCER, 2023, 23 (01)
  • [10] Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors
    Hong-Fei Zhu
    Jin-Kai Feng
    Yan-Jun Xiang
    Kang Wang
    Li-Ping Zhou
    Zong-Han Liu
    Yu-Qiang Cheng
    Jie Shi
    Wei-Xing Guo
    Shu-Qun Cheng
    BMC Cancer, 23
12345